NeuroSense Therapeutics Ltd

XNAS:NRSN 4:00:00 PM EDT

6.72

+0.23 (+3.54%)

6:22:37 PM EDT: $6.36 -0.36 (-5.36%)

Market Cap (Intraday)	12.75M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.54 Million
Adjusted EPS	-$0.79

See more estimates

10-Day MA	$7.28
50-Day MA	$9.89
200-Day MA	$15.13

See more pivots

NeuroSense Therapeutics Ltd Stock, XNAS:NRSN

11 HaMenofim Street, Building B, Herzliya, Tel Aviv 46725

Israel

Phone: +972.9.799.6183

Number of Employees: 18

http://www.neurosense-tx.com

Description

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including AlzheimerÃ¢â?¬â?¢s and ParkinsonÃ¢â?¬â?¢s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.